Stimulus-sensitive polymer drug conjugates based on high molecular weight N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers carrying doxorubicin via a pH-dependent cleavable bond (pHPMA-Dox) were previously shown to be able to overcome multi-drug resistance. Nevertheless, a tumor type dependent differential response was observed. Although an improved and more selective tumor accumulation of pHPMA-Dox is generally achieved due to the enhanced permeability and retention (EPR) effect, little is known about the fate of these conjugates upon entering the tumor tissue, which could explain the different responses. In this study, we compared in vitro and in vivo accumulation and Dox-activation of pHPMA-Dox in three cancer cell line models (1411HP, A2780cis, HT29) and derived xenograft tumors using a near-infrared fluorescence-labeled pHPMA-Dox conjugate. Firstly, cytotoxicity assays using different pH conditions proved a stepwise, pH-dependent increase in cytotoxic activity and revealed comparable sensitivity among the cell lines. Using multispectral fluorescence microscopy, we were able to track the distribution of drug and polymeric carrier simultaneously on cellular and histological levels. Microscopic analyses of cell monolayers confirmed the assumed mechanism of cell internalization of the whole conjugate followed by intracellular cleavage and nuclear accumulation of Dox in all three cell lines. In contrast, intratumoral distribution and drug release in xenograft tumors were completely different and were associated with different tissue substructures and microenvironments analyzed by Azan- and Hypoxisense®-staining. In 1411HP tumors, large vessels and less hypoxic/acidic microenvironments were associated with a pattern resulting from consistent tissue distribution and cellular uptake as whole conjugate followed by intracellular drug release. In A2780cis tumors, an inconsistent pattern of distribution partly resulting from premature drug release was associated with a more hypoxic/acidic microenvironment, compacted tumor tissue with compressed vessels and specific pre-damaged tissue structures. A completely different distribution pattern was observed in HT29 tumors, resulting from high accumulation of polymer in abundant fibrotic structures, with small embedded vessels featuring this tumor type together with pronounced premature drug release due to the strongly hypoxic/acidic microenvironment. In conclusion, the pattern of intratumoral distribution and drug release strongly depends on the tumor substructure and microenvironment and may result in different degrees of therapeutic efficacy. This reflects the pronounced heterogeneity observed in the clinical application of nanomedicines and can be exploited for the future design of such conjugates.

Institute of Macromolecular Chemistry Czech Academy of Sciences Heyrovský Sq 2 162 06 Prague 6 Czech Republic

Institute of Pharmacy Martin Luther University Halle Wittenberg 06120 Halle Germany

University Clinic for Internal Medicine 4 Hematology Oncology Medical Faculty of Martin Luther University Halle Wittenberg 06120 Halle Germany

See more in PubMed

Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzym. Regul. 2001;41:189–207. doi: 10.1016/S0065-2571(00)00013-3. PubMed DOI

Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Release. 2016;244:108–121. doi: 10.1016/j.jconrel.2016.11.015. PubMed DOI

Golombek S.K., May J.N., Theek B., Appold L., Drude N., Kiessling F., Lammers T. Tumor targeting via EPR: Strategies to enhance patient responses. Adv. Drug Deliv. Rev. 2018;130:17–38. doi: 10.1016/j.addr.2018.07.007. PubMed DOI PMC

Nichols J.W., Bae Y.H. EPR: Evidence and fallacy. J. Control. Release. 2014;190:451–464. doi: 10.1016/j.jconrel.2014.03.057. PubMed DOI

Nakamura Y., Mochida A., Choyke P.L., Kobayashi H. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? Bioconjug. Chem. 2016;27:2225–2238. doi: 10.1021/acs.bioconjchem.6b00437. PubMed DOI PMC

Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 2015;91:3–6. doi: 10.1016/j.addr.2015.01.002. PubMed DOI

Ojha T., Pathak V., Shi Y., Hennink W.E., Moonen C.T.W., Storm G., Kiessling F., Lammers T. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv. Drug Deliv. Rev. 2017;119:44–60. doi: 10.1016/j.addr.2017.07.007. PubMed DOI PMC

Nichols J.W., Sakurai Y., Harashima H., Bae Y.H. Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling. J. Control. Release. 2017;267:31–46. doi: 10.1016/j.jconrel.2017.08.003. PubMed DOI

Chytil P., Koziolova E., Etrych T., Ulbrich K. HPMA Copolymer-Drug Conjugates with Controlled Tumor-Specific Drug Release. Macromol. Biosci. 2018;18 doi: 10.1002/mabi.201700209. PubMed DOI

Duncan R. Development of HPMA copolymer-anticancer conjugates: Clinical experience and lessons learnt. Adv. Drug Deliv. Rev. 2009;61:1131–1148. doi: 10.1016/j.addr.2009.05.007. PubMed DOI

Kopecek J., Kopeckova P. HPMA copolymers: Origins, early developments, present, and future. Adv. Drug Deliv. Rev. 2010;62:122–149. doi: 10.1016/j.addr.2009.10.004. PubMed DOI PMC

Lammers T., Ulbrich K. HPMA copolymers: 30 years of advances. Adv. Drug Deliv. Rev. 2010;62:119–121. doi: 10.1016/j.addr.2009.12.004. PubMed DOI

Heinrich A.K., Lucas H., Schindler L., Chytil P., Etrych T., Mader K., Mueller T. Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance. Mol. Cancer Ther. 2016;15:998–1007. doi: 10.1158/1535-7163.MCT-15-0824. PubMed DOI

Callahan J., Kopeckov P., Kopecek J. Intracellular trafficking and subcellular distribution of a large array of HPMA copolymers. Biomacromolecules. 2009;10:1704–1714. doi: 10.1021/bm801514x. PubMed DOI PMC

Jensen K.D., Nori A., Tijerina M., Kopeckova P., Kopecek J. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J. Control. Release. 2003;87:89–105. doi: 10.1016/S0168-3659(02)00352-8. PubMed DOI

Chytil P., Hoffmann S., Schindler L., Kostka L., Ulbrich K., Caysa H., Mueller T., Mader K., Etrych T. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: Impact of release rate on biodistribution. J. Control. Release. 2013;172:504–512. doi: 10.1016/j.jconrel.2013.05.008. PubMed DOI

Hoffmann S., Vystrcilova L., Ulbrich K., Etrych T., Caysa H., Mueller T., Mader K. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release: Synthesis and characterization of distribution and tumor accumulation in mice by noninvasive multispectral optical imaging. Biomacromolecules. 2012;13:652–663. doi: 10.1021/bm2015027. PubMed DOI

Matsumoto Y., Nichols J.W., Toh K., Nomoto T., Cabral H., Miura Y., Christie R.J., Yamada N., Ogura T., Kano M.R., et al. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat. Nanotechnol. 2016;11:533–538. doi: 10.1038/nnano.2015.342. PubMed DOI

Adiseshaiah P.P., Crist R.M., Hook S.S., McNeil S.E. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat. Rev. Clin. Oncol. 2016;13:750–765. doi: 10.1038/nrclinonc.2016.119. PubMed DOI

Han X., Xu Y., Geranpayehvaghei M., Anderson G.J., Li Y., Nie G. Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors. Biomaterials. 2020;232:119745. doi: 10.1016/j.biomaterials.2019.119745. PubMed DOI

Miao L., Lin C.M., Huang L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J. Control. Release. 2015;219:192–204. doi: 10.1016/j.jconrel.2015.08.017. PubMed DOI PMC

Chan T.S., Shaked Y., Tsai K.K. Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers. Front. Oncol. 2019;9:688. doi: 10.3389/fonc.2019.00688. PubMed DOI PMC

Etrych T., Strohalm J., Chytil P., Cernoch P., Starovoytova L., Pechar M., Ulbrich K. Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting. Eur. J. Pharm. Sci. 2011;42:527–539. doi: 10.1016/j.ejps.2011.03.001. PubMed DOI

Etrych T., Daumova L., Pokorna E., Tuskova D., Lidicky O., Kolarova V., Pankrac J., Sefc L., Chytil P., Klener P. Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging. J. Control. Release. 2018;289:44–55. doi: 10.1016/j.jconrel.2018.09.018. PubMed DOI

Ulbrich K., Etrych T., Chytil P., Jelinkova M., Rihova B. HPMA copolymers with pH-controlled release of doxorubicin: In vitro cytotoxicity and in vivo antitumor activity. J. Control. Release. 2003;87:33–47. doi: 10.1016/S0168-3659(02)00348-6. PubMed DOI